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Yale University
Abstract
Data Integration and Targeted Anticancer Drug Synergies Prediction
by Xiaoting Gao
Chairperson of the Supervisory Committee:

Professor
Department of Biostatistics

In the past decades, targeted cancer therapies have made considerable
achievements in inhibiting cancer progression by modulating specific molecular
targets. However, targeted cancer therapies have reached a plateau of efficacy as the
primary therapy since tumor cells can achieve adaptability through functional
redundancies and activation of compensatory signaling pathways. Therapies using
drug combinations have been developed to overcome the bottleneck. Accurate
predictions of synergies effect can help prioritize biological experiments to identify
effective combination therapies. Data integration can give us a deeper insight into
the mechanism of cancer and drug synergies and help to address the challenge in
prediction of drug combinations. In this thesis, we illustrate that integrative analysis
of multiple types of omics data and pharmacological data can more effectively
identify drug synergies, hence improve the prediction accuracy. As part of the
AstraZeneca-Sanger Drug Combination Prediction DREAM Challenge, we showed
that multiple data integration methods could identify multiple oncogenes and tumor
suppressor genes as signature genes. We showed that several models built through
data integration outperformed benchmark models without data integration
methods.
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CHAPTER 1. INTRODUCTION

An understanding of the molecular basis of cancer brings the development of
targeted anticancer therapies. In the past decades, targeted cancer therapies have
made considerable progress in inhibiting cancer progression in some cancer
patients by modulating specific molecular targets. However, the development of
new drugs has been slowed down in recent years partly because drugs with specific
targets often show limited efficacies, poor safety and resistance profiles [1]. One of
the reasons of this phenomenon is that most human diseases are results of complex
biological processes that are redundant and robust to drug perturbations of a single
molecular target. Therefore, in recent years, efforts have been directed to the
discovery of compound combinations, as they exhibit several advantages as
therapeutics compared to single agent medicines. Drugs in combination may
achieve greater effects than the additive therapeutic effect of each drug individually,
which is known as synergy [2]. For example, Gefitinib (EGFR tyrosine kinase
inhibitor, induces CDK inhibitors p27 and p21, decreases MMP2 and MMP9 enzyme
activity [3]), combined with Taxane (disrupts microtubules by binding to β-tubulin,
induces tumour suppressor gene p53 and CDK inhibitors p21, downregulates BCL-2,
leading to apoptosis [4]) can produce strong synergistic effect in breast cancer
MCF7/ADR cells [5]. Studies have also suggested that synergistic drug combinations
can achieve therapeutic selectivity by countering biological compensation, allowing
reduced dosage of each compound or accessing context-specific multitarget
mechanisms [6].
1.1

Targeted anticancer drug synergies and omics data

For single agent therapeutics, predicting the response of a cancer patient to a
certain targeted anticancer drug is vital for precision medicine. The efficacy of
personalized treatment depends on the ability to identity specific genetic causes for
a patient and then use the corresponding targeted therapy. In order to have a
6

comprehensive understanding of the link between genomic features and treatment
effects, large-scale datasets of genomic, proteomic, epigenomic profiling data as well
as pharmacological profiling data have been generated from cultured human cell
lines, such as the Cancer Cell Line Encyclopedia (CCLE) [7] and Cancer Genome
Project (CGP) [8]. In 2012, NCI-DREAM drug sensitivity prediction challenge was
held aiming to compare methods for predicting drug sensitivity from multi-omic
data in breast cancer cell lines, including copy number variation, gene expression,
mutation, DNA methylation and protein abundance [9]. The key to precision
medicine will be the ability to “translate large compendia of genomic, epigenomic,
and proteomic data into clinically actionable predictions” [9]. Studies from this
challenge have illustrated that the incorporation of multiple genomic
characterizations could lower the prediction error for single drug sensitivity [9, 43].
Similarly, the accuracy of prediction of drug synergies also largely depends on our
comprehension of how different types of omics data can inform us on synergistic
effects. Knowledge drawn from multi-omic data can facilitate progress in
understanding mechanisms of drug combinations. Omics data have been widely
used to investigate the relations among small molecules, genes and diseases and to
discover molecules linked to pathological processes. With its ability to reflect
biological processes, omics data can also contribute to drug combinations studies.
Some research has been done to predict drug synergies or to construct novel
molecular networks based on omics data. Chen et al. [28] presented a systematic
overview of existing approaches to model drug synergies, including omic-based
methods in synergy identification. Sun et al. [29] proposed a model for the
prediction of synergistic drug combinations specifically for the treatment of cancer,
called Ranking-system of Anti-Cancer Synergy (RACS), which could combine
features of targeting networks and transcriptomic profiles. A computational
approach, Drug-Induced Genomic Residual Effect (DIGRE) Computational Model,
was proposed to predict drug synergies by explicitly modeling drug response curves
and gene expression changes after drug treatments [30]. Chen [31] proposed a new
method for synergy evaluation by a pathway-pathway interaction network. Vera7

Licona et al. [40] designed a new software, OCSANA (optimal combinations of
interventions from network analysis), to identify optimal and minimal combinations
of intervention to disrupt the paths between source nodes and target nodes while
minimizing the side effects. In Pal & Berlow’s article [42], a new approach was
presented to predict the sensitivity of a new drug or a drug combination by
generating abstract representation of cancer pathways based on known kinases
inhibitor targets. These studies have illustrated the possibility of predicting drug
synergistic effect from omics data.
1.2

Data integration

Although many methods have been developed for drug combination effect
prediction using omics data, most of these methods mainly utilize one type of omics
data, usually genomics data or proteomics data. However, with the rise of highthroughput sequencing technologies [10] and large-scale consortia projects, large
amounts of heterogeneous datasets have been generated, which make integration of
different types of omics data an effective approach to understand the complex
interplay of drug combinations against the disease process. Several studies have
stated the necessity and benefit of data integration methods in drug related studies
[33, 34, 35]. Dorel et al. [39] discussed three integration strategies to predict drug
sensitivity and intervention combinations using signaling networks together with
high-throughput data: (1) Highthroughput data-based signature retrieval; (2)
Inferring intervention points from integrated analysis of interactomes and (3)
Interference set finding using topological analysis of networks and mathematical
modeling of network rewiring. Zhao et al. [32] presented a computational approach
to predict drug combinations. By integrating molecular and pharmacological data,
69% of their top ranked predictions of effective combinations were supported by
literature. Azmi et al. [41] showed that combining high-throughput data with
network and systems biology-based strategy could facilitate the understanding of
the synergy between MI-219 and oxaliplatin at the gene level and aid to identify
driver pathways that augment p53 reactivation-mediated events.
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In this thesis, data integration refers to the process of selecting important predictors
of drug synergies by conducting integrative analysis of genomics, epigenomics,
transcriptomics and pharmacological data. To understand drug combination in gene
interaction network, there is a need to develop data integration methods because
different types of molecules are involved in a biological process and the analysis of
one data type may give a partial, and maybe biased, perspective on the biological
process. Although microarray technology seems to be the most mature technology
from all the omics and many breakthroughs about predicting cancer outcomes from
gene expression data have been made, other omics data may contain
complementary information not present in gene expression and integrating more
than one data source can achieve better prediction of therapy response [38]. It was
shown that a set of genes selected by analyzing the correlation of copy number
variation and gene expression could discriminate matched adjacent noncancerous
samples from gastric cancer samples in an unsupervised two-way hierarchical
clustering [11]. Some research found a negative correlation between activities of the
enzyme drug L-asparaginase and DNA copy number of genes near asparagine
synthetase in the ovarian cancer cells [12].
Assembling all types of omics data into a more comprehensive and complex
biological entity can shed light on the biological processes about cancer and
targeted drugs that are not fully known to us. In our study, datasets from the
AstraZeneca-Sanger Drug Combination Prediction DREAM Challenge, including gene
expression, copy number variation, mutation and methylation, were used to
illustrate the benefit of applying data integration methods into drug synergy
analysis.
CHAPTER 2. RESEARCH DESIGN

2.1

Overview

Our study of the data integration methods in drug synergy study is part of our
research for the AstraZeneca-Sanger Drug Combination Prediction DREAM
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Challenge, Subchallenge 1. The aim of this Challenge is to “explore – and hopefully
reveal - fundamental traits that underlie effective combination treatments and
synergistic drug behavior using baseline genomic data, i.e. data collected
pretreatment” [13]. It is to “uncover important biomarkers that are predictive of
synergistic behavior, yielding a direct path for clinical translation” [13]. Synergy
scores of 167 experimentally tested drug combinations over 85 cell lines (primarily
colon, lung and breast) were provided. Corresponding monotherapy drug response
for each drug and cell line were available as well. Additionally, omics data for 85 cell
lines including gene expression, somatic mutation, copy number variation and
methylation were offered. Putative drug targets and chemical information about
drugs were also known to participants.
In Subchallenge1, participants were asked to predict drug synergy of 167
combinations in the panel of 85 cell lines. The synergy dataset was divided into
three sets: a training data set (3/6-50%), a leaderboard set (1/6-16.7%), and a
validation set (2/6-33%). In this study, the training dataset and leaderboard dataset
were used since validation set has not been released yet. There are two challenges
with different restrictions in Subchallenge 1. For Subchallenge 1A (we will use
Challenge A in the following text instead), all available data could be used; while for
Subchallenge 1B (Challenge B in the following text), only copy number variation,
mutation and prior knowledge was allowed [13].
In our study, our main assumption is that combination effects on cell lines with
similar molecular features would resemble each other. We implemented our model
based on Random Forests, a method widely used and demonstrated to be powerful
in various supervised learning problems. Random Forests are a classifier consisting
of a collection of tree-structured classifiers [36]. To predict drug synergy scores,
Random Forests fitted a combination of regression trees. The predictions from each
tree were taken and averaged together to predict new values from this ensemble of
trees. We first identified signature genes associated to the cancers and/or
influenced by the drugs. Ten sets of signature genes were selected from different
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perspectives. To demonstrate the effect of data integration techniques on drug
synergy prediction, six of the ten sets of signature genes were selected by
integrative analysis while four of them were selected without integrative analysis.
Then ten Random Forests models were constructed to automatically choose
important molecular features for each combination from the signature genes by
including additional covariates such as drug indicators in the regression model.
Four models using signature genes not selected by data integration methods were
considered benchmark models. The performance of six other models would be
compared to the performances of these four models.
2.2
2.2.1

Methods

Data preprocessing

Somatic mutation data were preprocessed using MutSigCV [14], a method to
extrapolate the likelihood for each gene of being cancer-associated based on the
mutation position, transition status and mutation type. The original chromosome
region-based methylation data were converted to gene-based data using R package
BioMart [15]. For copy number variation (CNV) data, the maximal copy number
information was taken out from GRCh37 CNV file and the non-informative (equalvalued) genes were removed across cell lines, thus CNV data were transformed into
a matrix with each entry representing the maximum copy number of a given gene in
the corresponding cell line. For single drug sensitivity, the GI50 of a drug on a cell
line was calculated using the fitted dose-response curves from the mono-therapy
data.
2.2.2

Signature gene selection

The following methods were applied to select signature gene
expression/mutation/copy number variation/methylation to be added into the
model.
1. DriverNet [16]
DriverNet is a novel integrated genome/transcriptome analysis approach to
identify candidate drivers with aberrant genomic alteration such as mutation or
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copy number variation [16]. The assumption of DriverNet is that driver genes
with genomic aberration will impact the expression levels of multiple genes
rather than a single gene. Genes with more connections to genes with outlying
expression are more likely to be driver genes. The associations between
mutation/copy number variation and coincident changes in gene expression are
analyzed through an influence graph based on prior knowledge about pathways
and gene networks obtained from Reactome [17]. Then a greedy algorithm is
applied to find the lowest number of genes connected to the most genes with
outlying expression.
The expression of a gene in a sample is defined as an outlying expression if it is
outside of a predetermined range of gene expression for a given gene across all
samples. In this manner, gene expression matrix will be converted to a binary
matrix with samples as rows and genes as columns. Mutation matrix and copy
number variation matrix are both binary matrices, with cells having a value of 1
if the gene is mutated or has copy number gain/loss in the corresponding sample
and 0 otherwise. The associations between gene expression and mutation, or
copy number variation are examined by an influence graph, which contains prior
knowledge about the protein functional interaction network derived from Wu’s
study [26].
In our study, DriverNet generated two signature gene lists. One is the result of
analyzing mutation and gene expression data while the other is for copy number
variation and gene expression.
2. remMap [18]
RemMap, REgularized Multivariate regression for identifying MAster Predictors,
was proposed to fit multivariate response regression models under the highdimension-low-sample-size setting [18]. The motivation of remMap is to explore
the regulatory relationships among different biological molecules from multiple
types of high dimensional genomic data, especially the modulation effect of copy
12

number variation on gene expression [18]. RemMap can build a multivariate
linear regression model with an L1 norm penalty to control the overall sparsity
of the coefficient matrix and a group lasso penalty [19] to control the total
number of predictors entering the model. Consequently, the detection of master
predictors can be facilitated.
Peng et al. [18] applied remMap method to gene expression and copy number
variation data to investigate the influences of DNA copy number alterations on
RNA transcript levels based on 172 breast cancer tumor samples. RemMap can
also be utilized to study the relationships between other types of biological
molecules [18]. It can be applied to other models as well to select a group of
variables in a multiple regression model. In our study, remMap was utilized to
select genes whose expression could affect single drug sensitivity.
3. CNAmet [20]
The assumption of CNAmet is that genes with simultaneous alterations in gene
expression, copy number and methylation are likely to be involved in tumor
progression. CNAmet can integrate copy number, methylation and gene
expression data to detect genes with abnormal expression levels that have
concomitant amplification/deletion or hypomethylation/hypermethylation.
In our study, CNAmet was applied to analyze copy number variation,
methylation and gene expression to select signature genes. It was also used to
identify corresponding changes in copy number and methylation for genes
selected by remMap since remMap was only used to select genes of which
expression levels can influence single drug response.
4. COSMIC gene
COSMIC Cancer Gene Census data [21] contains a catalog of genes for which
mutations have been causally implicated in cancer. We selected genes related to
the cancer types of the cell lines considered in this challenge, resulting in 81
genes as signature genes. Random forests models with the
13

expression/mutation/copy number/methylation of COSMIC genes as predictors
were benchmark models in our study. Prediction results of other models using
signature gene lists generated by data integration methods would be compared
to the results of these models.
5. Coefficient of variation
A total of 300 genes with the highest coefficients of correlation of gene
expression levels were selected as signature genes. In our study, a model to
predict drug synergies was built with the gene expression, copy number
variation and methylation of these genes. This model was another benchmark
model to assess the effect of utilizing data integration methods to select
signature genes.

2.2.3

Drug synergies prediction

For each drug combination on each cell line, a vector of covariates was constructed.
The vector was comprised of the following covariates:
•

Drug indicators: which two drugs the combination included;

•

Cell line indicators: on which cell line the combination was tested;

•

CNV indicators: whether the target genes of the two drugs have copy number
variations (e.g. maximal copy number 3) on the cell line;

•

Mutation indicators: whether the target genes of the two drugs have
mutations on the cell line;

•

The CNV, gene expression, and methylation information of the signature
genes on the cell line.

Random Forests implemented using R package randomForest [22] was applied to
predict drug synergy scores of every drug combination on different cell lines. The
response variable, i.e., observed synergy scores, was preprocessed by subtracting
the mean of the corresponding combination from them. Then the mean was added
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back to the Random Forests predictions. For both Challenge A and Challenge B,
benchmark models and models using data integration approaches were built.
2.2.4 Performance evaluation
In our study, the training and leaderboard datasets were combined to train the
Random Forests. To assess the performance of each model, 30 rounds of 3-fold cross
validations were conducted. In this Dream Challenge, two prediction scoring metrics
were designed to compare the prediction accuracy of each model. In our study, we
adopted the same metrics to measure each model’s prediction precision.
1. Primary metric [27]
Primary metric is aimed to evaluate the prediction accuracy of each drug
combinations. It is a weighted average of Pearson correlation between
predicted synergy scores and true synergy scores for each drug combination.
Suppose for drug combination i, n! is the number of cell lines drug
combination i was applied to and ρ! is the Pearson correlation between
synergy score prediction and true synergy score for drug combination i, then
𝑃𝑟𝑖𝑚𝑎𝑟𝑦 𝑚𝑒𝑡𝑟𝑖𝑐: 𝜌! =

!
!!! 𝑛! − 1
!
!!! 𝑛! −

∙ 𝜌!
1

,

where N = 167 is the total number of drug combinations (∀ n! ≥ 2).
2. Tie metric [27]
The tie-breaking metric is identical to the primary metric, but only drug
combinations with observed synergistic cell lines in the test set are used. For
each drug combination, synergistic cell lines are defined as having synergy
score greater than 20 in that cell line for a given drug combination.
Since 30 rounds of 3-fold cross validations have been conducted, the mean primary
metric and tie metric were used to compare the performances of all models.
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CHAPTER 3. RESULTS

3.1

Feature selection

3.1.1

DriverNet

The underlying assumption of the DriverNet method is that aberrant genomic
variation will disrupt transcriptional patterns through one or several pathways. The
copy number alteration or somatic mutation of one gene may not only lead to the
over-representation or under-representation of this gene, but also the expression
levels of other genes connected to it through pathways. Similarly, one mutated gene
can also affect multiple genes. For our analysis, DriverNet was first applied to
mutation and gene expression datasets to select candidate driver mutations. Then it
was applied to copy number variation and gene expression datasets again, aiming to
detect possible driver copy number variation.
For mutation only, DriverNet identified 326 mutated genes that were associated
with abnormal expression levels of other genes. A total of 97 of them were
nominated as significant driver candidates with P value below 0.05, including
several known oncogenic genes, such as PIK3CA, KRAS, ERBB2, STAG1, as well as
tumor suppressor genes TP53 and PTEN. Among 97 significant candidate drivers
identified by DriverNet, 21 of them were in the COSMIC cancer gene census (ABL1,
AKT1, APC, ATM, BCR, CDH1, EGFR, EP300, ETNK1, FBXW7, JAK1, KRAS, MET, MSH2,
PDGFRA, PDGFRB, PIK3CA, PIK3R1, PTEN, SMAD4, TP53). Other candidate genes
that were not in COSMIC datasets included FCL1, of which missense mutations,
silent mutations and nonsense mutations are often observed in cancers, and RYR3,
which may affect the growth, morphology and migration of breast cancer cells [23].
For copy number variation, 96 genes with amplification and 190 genes with deletion
were marked as candidate drivers by DriverNet. Among amplified candidate genes,
the copy number variation of 15 of them significantly altered the gene expressions
of themselves or other genes, while the copy number loss of 32 genes of 190 deleted
genes had significant altering effects. Significant candidate drivers (p<0.05) with

16

high-level amplification or homozygous deletion included oncogenes EGFR, PIK3CA,
MET and suppressor gene TP53. Oncogenes AKT1, FGFR1 and FGFR2 were also
detected but not significant. Most signature genes selected by DriverNet identified
were associated with the aberrant gene expression levels of other genes. For
example, the amplification of oncogene PIK3CA was found to be associated with the
up-regulation of 43 other genes, including EGFR, MAPK9, PRKCA, and EP300.
Figure.1 shows the heat map of Spearman correlation between copy number and
gene expression of 46 genes selected with p value lower than 0.05.
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Figure 1 Spearman correlation between CNV and expression: Rows correspond to gene expression and
columns correspond to copy number. Red and blue indicate high and low correlations respectively. The
plot shows that the copy numbers of selected genes are associated with the expression of other genes
beside themselves. The copy numbers of gene FURIN are negatively associated with the expression of
almost all the other selected genes. The copy numbers of COX7B are positively associated with the
expression of all the selected genes.

Surprisingly, ERBB2, of which the amplification exists in up to 18% of breast cancer
patients, was not identified as a candidate driver [24]. However, the average gene
expression level of ERBB2 with amplification was significantly higher than that of
ERBB2 with deletion or without any copy number variation. Figure 2 is the boxplot
displaying the gene expression levels of ERBB2 with and without amplification. The
results of t test of equal means of gene expression are presented as well.
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Mean
4.87
(amplification)
Mean
4.19
(deletion/ no
change)
P value
0.02

Figure 2 Boxplot of the expression of ERBB2: Amplified ERBB2 has relatively higher expression levels
than ERBB2 without amplification. The P value of the two-sample t-test for the equal mean is 0.02. Thus,
from the results of t test, the expression level varies with the copy number of gene ERBB2.

The candidate driver genes were predictors for both Challenge A and Challenge B.
For the models for Challenge B, only the copy number variation and mutation of
those genes were added.
3.1.2

CNAmet

CNAmet was applied to select genes with simultaneous expression and copy number
(or methylation) alterations. Those selected genes, which may have a key role in
tumor progression or drug interaction, were used as predictors for Challenge B.
Our analysis of copy number variation, gene expression and mutation datasets using
CNAmet resulted in four gene lists, which corresponded to hypomethylation,
hypermethylation, copy number loss, and gain respectively. The copy numbers
(methylation) of genes in copy number gain and loss (hypomethylation and
hypermethylation) lists were predictors in the model. CNAmet identified 487 genes
with both amplification and overexpression, or deletion and underexpression. A
total of 369 genes with methylation alterations were detected coexisting with
downregulation or upregulation of gene expression. The overlaps between them
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were 52 genes, of which both copy numbers and methylations affected their gene
expressions. JAK1, whose mutation is often associated with acute lymphoblastic
leukemia and one of the drug target genes, was selected as a predictor since its
amplification and hypomethylation were linked to the abnormal gene expression
levels.
Candidate signature genes nominated by CNAmet included several oncogenes such
as FLT3, STAT3, and AKAP9, and 5 drug target genes, JAK1, PIK3CA, RRM1, TYMS,
and TOPBP1. Similar to DriverNet, CNAmet did not label ERBB2 as a signature gene.
The p value of permutation test for ERBB2 is 0.21.
3.1.3

remMap

Unlike DriverNet and CNAmet, which identify possible driver genes or signature
genes without utilizing drug information, remMap allows using single drug
responses as the dependent variable to select features that affect drug sensitivity. In
theory, drug synergy scores can also be applied as the response variable for variable
selection. However, due to the small number of experiments with cell lines for each
drug combinations, the limited sample size can lead to low statistical power, hence
reduce the chance of detecting signature genes. Therefore, the GI50 value of each
drug was used as response variable since there were fewer missing observations for
each drug. Figure 3.A and Figure 3.B display two plots, one of which is the heat map
of drug synergy scores of all the drug combinations across 85 cell lines and the other
is of GI50 values of all drugs across all cell lines.
With GI50 values as response variable, if the predictors in the multivariate linear
model were the expression, copy number variation, mutation and methylation of all
genes, theoretically remMap could simultaneously select all the important features.
Nevertheless, it would take exceptionally long time to run this program. Even using
gene expression values along as predictors in the model requires more than five
days to run the program. Considering the computational time, only gene expressions
with coefficient of correlation greater than 0.2 were added into the model as
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independent variables. As a
result, 2922 predictors
were considered in the
model. As is shown in
Figure 3.A, not all drugs
were tested on the same
cell lines. Consequently, we
divided 69 drugs into five
groups that were not
mutually exclusive based
on the cell lines they tested
on and built a model for
each group of drugs; hence
Figure 3.A GI50 and Cell Lines

we had 5 gene lists
corresponding to 5 drug
lists.
There were 569 genes
selected by remMap,
including drug target genes
PIP5K1B, WNT5B,
WNT10A, and others. The
results are consistent with
existing biological findings
on cancer. For example, for
drugs targeting MAP2K1
and MAP2K3, this method
successfully inferred the
association between cell
lines’ response to those

Figure 4.B Drug Synergy Scores and Cell Lines
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drugs and the expression of genes FGFR3, MAPK13 and FGF12.
However, as a result of data preprocessing, only a small portion of gene expression
data was used, which may result in the failure to capture important information
from genes whose expression levels had less variation. Therefore, the gene list
selected by remMap was combined with a list of 81 genes from COSMIC data that are
related to the cancer types in this challenge and then the gene expression data of
this new list served as predictors in the final model. Figure 4 is the heat maps of
Pearson correlations between GI50 of five drugs, which were tested on more cell
lines than other drugs, and expression levels of genes selected by remMap
corresponding to these drugs. Figure 5 shows Pearson correlations between GI50 of
the same five drugs and COSMIC gene expressions.

Figure 4 Pearson Correlations between Single Drug Sensitivities and Gene Expressions of 50 genes
selected by remMap. Blue and Red indicate low and high correlations. Rows correspond to drugs and
columns correspond to gene expression. The plot suggests that the expression levels of selected genes
can affect drug responses. The highest positive correlation is detected between the expression of gene
ALOX15B and the response of drug “MTOR_1”, which is as high as 0.63. The most significant negative
correlation is between the expression of gene OSMR and the response of drug “PIK3C”, which is -0.43.
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Figure 5 Pearson Correlations between Single Drug Responses and Gene Expression of COSMIC genes.
Blue and Red indicate low and high correlations. Rows correspond to drugs and columns correspond to
gene expression. Compared to genes selected by remMap, the correlations between drug responses and
the expression of COSMIC genes are less strong but strong associations still exist. The expression of ETV1
is negatively correlated with the response of drug “AKT”. The Pearson correlation between them is -0.43.
The highest positive correlation is 0.41, which is the correlation between the expression of GATA3 and
the expression of drug “AKT”.

Because only related gene expression features were selected, it is not known
whether the copy number variation or methylation of those genes were associated
with drug responses. Therefore, CNAmet method was applied again to find those
parallel changes. A total of 16 of them were identified as having simultaneous copy
number variation, while for methylation, 14 of them were detected with
hypermethylation or hypomethylation that can impact drug responses.
3.2

Model Performance

Ten models were built to predict drug synergy scores. Six of them were for
Challenge A and the others were for Challenge B, in which only copy number
variation and mutation data were allowed to use. For the models of each challenge,
the difference of the covariates used lies in the gene expression/copy number
variation/methylation of signature genes added into the model. Each model used
different signature gene lists generated by multiple methods. Table 1 summarizes
which of the CNV, gene expression and methylation information was specifically
used in each model.
23

Table 1.A Features of Signature Genes in Each model for Challenge A

Challenge A
Model
DriverNet1

Covariates
1. Expression levels of genes selected by DriverNet using
mutation dataset and gene expression dataset;
2. Copy numbers of those selected genes;
3. Methylation levels of selected genes.

DriverNet2

1. Expression levels of genes selected by DriverNet using copy
number variation dataset and gene expression dataset;
2. Copy numbers of selected genes;
3. Methylation levels of selected genes.

remMap.CNAmet

1. Expression levels of 569 genes selected by remMap;
2. Expression levels of 81 COSMIC genes related to the cancer
type in this challenge. (Overlapping genes in two gene lists
were removed so that there were no redundant genes).
3. Copy numbers of 16 genes with simultaneous amplification
or deletion selected by CNAmet;
4. Methylation levels of 14 genes with parallel
hypermethylation or hypomethylation selected by CNAmet.

remMap

1. Expression levels of 569 genes selected by remMap;
2. Expression levels of 81 COSMIC genes related to the cancer
type in this challenge. (Overlapping genes in two gene lists
are removed so that there will be no redundant variables).

COSMIC
(benchmark)

1. Expression levels of 81 genes from COSMIC Cancer Gene
Census related to the cancer type in this challenge;
2. Copy numbers of selected genes;
3. Methylation levels of selected genes.
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CV300
(benchmark)

1. Expression levels of 300 genes with the highest coefficient
of variation of their gene expression levels;
2. Copy numbers of selected genes;
3. Methylation levels of selected genes.

Table 1.B Features of Signature Genes in Each model for Challenge B

Challenge B
Model

Covariates

DriverNet1 (B)

Copy numbers of genes selected by DriverNet using the
mutation dataset and gene expression dataset.

DriverNet2 (B)

Copy numbers of genes selected by DriverNet using the copy
number variation dataset and gene expression dataset.

CNAmet

Copy numbers of 487 genes selected by CNAmet with
simultaneous amplification or deletion and abnormal gene
expression.

COSMIC (B)
(benchmark)

Copy numbers of 81 genes from COSMIC Cancer Gene Census
related to the cancer types in this challenge.

In order to understand whether the application of data integration would benefit
drug synergy prediction, three benchmark models were built without using data
integration tools. Two of them, model CV300 and model COSMIC were for Challenge
A and model COSMIC (B) was for Challenge B.
The models’ performance was evaluated using two metrics designed by challenge
organizers, primary metric and tie metric. To compare ten models’ prediction
accuracy, 30 rounds of 3-fold cross validations were conducted. The mean primary
and tie metrics for the entire cross validations were calculated (Figure 6 and Table 2
display the two metrics for each model).
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Figure 6 Primary and Tie Metrics for Each Model: Purple bars indicate primary metric and blue bars indicate tie metric. The bars plot shows
that model DriverNet1 and model DriverNet1(B) achieve the highest prediction accuracy. Model CV300 has the lowest prediction scores.

Table 2.A Primary and Tie Metrics of Each Model in Challenge A

Model

DriverNet1 COSMIC DriverNet2 remMap remMap.CNAmet CV300

Primary 0.273

0.268

0.268

0.265

0.266

0.199

0.272

0.272

0.270

0.270

0.201

metric
Tie

0.278

metric
Table 2.B Primary and Tie Metrics of Each Model in Challenge B

Model

COSMIC (B)

DriverNet2 (B) DriverNet1 (B) CNAmet

Primary

0.266

0.261

0.272

0.240

0.270

0.267

0.278

0.246

metric
Tie metric

Based on the results of cross validations, model DriverNet1 and model DriverNet1
(B) achieved the best performance among models for Challenge A and for Challenge
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B respectively. Among six models for Challenge A, model CV300 had the lowest
primary and tie metrics. All other models, including models for Challenge B,
outperformed model CV300. This indicates that genes in all the other signature gene
lists contain more information than the genes whose gene expression have the
highest coefficient of variation of gene expression.
For Challenge A, compared to model COSMIC, the only model with better prediction
accuracy was model DriverNet1. Model DriverNet2 had the same performances as
Model COSMIC. All the other models for Challenge A did not achieve better
performance, but the differences in the performances were minimal. Model
DriverNet1 and model DriverNet2 both had higher primary metric and tie metric
than those of model remMap, even though signature genes used in model remMap
were selected with single drug response as dependent variable. Model
remMap.CNAmet’s performance was slightly better than model remMap. The
improvement was minimal and Pearson correlation between the predictions of two
models was 0.993. One probable reason is that although CNAmet was employed to
pinpoint related changes in copy number or methylation, only 30 genes were
detected with concurrent copy number variation or methylation alteration. The
effects of extra 30 features can be too limited to bring considerable improvement.
For Challenge B, the prediction of model DriverNet1 (B) was the most accurate. The
performances of model COSMIC (B) and model DriverNet2 (B) were very similar,
while the primary and tie metrics of model CNAmet were both lower. Therefore, the
genes selected by DriverNet using mutation data and gene expression data are most
informative for predicting drug synergy scores.
Unexpectedly, the predictions from different models are highly correlated, though
the covariates they use have little overlap. For each drug combination, we calculated
Pearson correlations between the predictions and true synergy scores. Besides
model CV300, model CNAmet, which had relatively lower prediction accuracy, other
seven models’ prediction were close. Figure 7 shows Pearson correlations of all
models besides model CNAmet, model CV300 and model remMap.CNAmet. Since
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Pearson correlation between the predictions of model remMap and the predictions
of model remMap.CNAmet was 0.993, only model remMap’s predictions are used
here.

Figure 7 Pearson Correlations between the Predicted Synergy Score and True Score of All the Drug Combinations. As shown
in the plot, each model has similar patterns of correlations. The predicted scores of each model are very similar.
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CHAPTER 4. CONCLUSIONS

4.1

Summary

In this thesis, we built ten Random Forests models to predict drug synergy scores.
Besides three models as benchmarks (model CV300, model COSMIC and model
COSMIC (B)), the other seven models utilized the copy number
variations/expressions/methylation levels of genes selected by DriverNet, remMap
and CNAmet. DriverNet selected 326 mutated genes with altered gene expression
using mutation and gene expression data. Another 286 genes with simultaneous
copy number variation and gene expression changes were selected by DriverNet
after analyzing copy number and gene expression data.
The results of the cross validations suggest that for Random Forests model,
signature genes selected by DriverNet using gene expression and mutation, or copy
number variation are the most predictive, in that model DriverNet1 and model
DriverNet1 (B)’s primary metrics were the highest (0.273 and 0.272). Especially for
Challenge B, when gene expression values cannot be used as predictors, DriverNet
identifies informative copy number variations successfully.
Although DriverNet cannot integrate drug response or drug synergies information
into the variable selection process like remMap, DriverNet1 and DriverNet2
outperformed two models using the gene list generated by remMap (model remMap
and model remMap.CNAmet), of which primary metrics were 0.265 and 0.266
respectively. One of the explanations that the genes selected by remMap were not as
informative as genes selected by DriverNet might be that due to the limited samples
of single drug responses, the power of detecting signature genes was limited.
Moreover, unlike DriverNet, which incorporates prior knowledge from existing
cancer research through an influence graph, remMap selects signature genes
without prior biological knowledges. Thus, when there is much noise in the dataset,
uninformative variables may be selected by remMap, hence decreasing model’s
prediction accuracy.
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Compared to DriverNet, CNAmet can conduct integrative analysis of copy number
variation, gene expression and methylation. This method is able to distinguish
synergistic effect of DNA methylation and copy number variation on gene
expression. Model CNAmet’s predictions were more accurate than those of Model
CV300 with primary metric as 0.240, which reveals that genes selected by CNAmet
are more helpful for drug synergies prediction.
For three benchmark models, model CV300, model COSMIC and model COSMIC (B),
model CV300 achieved the lowest prediction accuracy with primary metric as 0.199,
while the other two models with 81 genes related to the cancer types in this
challenge from COSMIC Cancer Gene Census as covariates had the best
performances other than model DriverNet1 and model DriverNet1 (B). For
Challenge A, model COSMIC had the second highest primary metric, 0.268; while for
Challenge B, model COSMIC (B)’s primary metric, 0.266, was the second highest as
well. Since all the model’s predictions were more precise than that of model CV300,
DriverNet, remMap and CNAmet are all effective ways to select signature genes. The
fact that model DriverNet1 and model DriverNet1 (B) had the best performance
suggests that information from genes selected entirely based on prior knowledge
(81 COSMIC genes) can be inadequate to predict drug synergies. Nonetheless, the
performance of models utilizing remMap and CNAmet to select features indicates
that variable selection methods that are not knowledge-based may also be
insufficient.
4.2

Limitations

Although this study has shown that the application of data integration methods can
improve model’s prediction accuracy, the implementation of data integration
methods has some limitations. First of all, each data integration method has its own
limitations.
1. DriverNet
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The most distinguishing feature of the DriverNet approach is to incorporate
prior knowledge about cancer gene networks through the influence graph. Genes
outside the influence graph will not be selected, which can reduce the likelihood
of including uninformative gene features in the model. Although in this study,
drug-gene information was not applied to select signature genes, theoretically it
is possible to use such information by designing our own influence graph.
However, the use of influence graph can also fail to identify signature genes we
have no knowledge of since the graph is inevitably sparse and incomplete.
Another drawback of DriverNet is that it may fail to detect somatic mutations or
copy number variations that modulate less extreme but important changes in
gene expression, in that a prespecified threshold is used to define outlying gene
expression values [16]. In our study, gene expressions outside the two standard
deviation values were considered abnormal. This approach may result in the
overlook of genes with somatic mutations or copy number variations that
modulate important changes in gene expression within the given range [16].
In addition, DriverNet cannot take the directionality of the change in expression
into account [16], and it cannot discern the correlation between copy number
gain/loss and gene expression is negative or positive.
2. CNAmet
Compared to DriverNet, which can identify genomic aberrations altering more
than one transcriptional network [16], the main limitation of CNAmet is that it
can only analyze the one-to-one association between gene expression and
methylation (or CNV). It cannot be applied to assess the influence of one gene’s
CNV or methylation on another gene’s expression. For example, in our study,
both DriverNet and CNAmet identified PIK3CA as signature gene. Both
approaches can recognize the effect of the copy number gain of PIK3CA on its
gene expression, but DriverNet can also distinguish the influence of amplified
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PIK3CA on gene expression of other genes in the same pathway, such as EGFR,
MAPK9, MET, GNAS, CD4, and others.
One of the advantages of CNAmet is that it can conduct integrative analysis of
methylation, copy number variation and gene expression. In our study, we only
used CNAmet to select genes with important hypermethylation or
hypomethylation. (remMap can select alteratinos in methylation with significant
effect as well, however, in our study, we only applied remMap to select signature
genes based on their expression since adding more variables into the model
would cost longer time to run the program). Nevertheless, CNAmet, like
DriverNet has the same disadvantage that directionality is not considered.
CNAmet does not employ prior knowledge, which makes it a suitable tool to
detect concomitant copy number/methylation and gene expression alteration,
but less applicable for signature genes selection. Although there is no clear
evidence that knowledge-based integration can outperform data-driven
integration, Kim et al.’s paper, in which a graph-based framework for integrating
multi-omics data to predict clinical outcomes for cancer patients was proposed,
suggested that it was beneficial to incorporate genomic knowledge, such as
pathway or GO gene sets, into omics data integration process since it could
improve the predictive power and better explain the interplay between different
types of data and knowledge [37]. However, CNAmet can serve as a
complementary tool for detecting matching alterations in methylation or copy
number for signature genes selected by other non-integrating methods. In our
study, after selecting signature genes with remMap, CNAmet was applied to
search for the parallel changes in methylation or copy number.
3. remMap
Compared to two other methods, remMap has two main strengths. First,
information about drug can be used to select signature genes. Second, remMap
treats all sources of genomic information as one coherent dataset rather than
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separate ones. Therefore, remMap can carry out one joint analysis by viewing
gene expression, methylation, copy number variation, and mutation datasets as
one dataset. Although in our study, due to the limited sample size and
computational feasibility, only gene expression dataset was used.
Because remMap is time-consuming, proper dimensionality reduction methods
should be applied first before using remMap for variable selection. Using original
high-dimensional datasets directly can be inefficient. Moreover, it is also hard for
remMap to incorporate prior knowledge into the model. Microarray technique
suffers from low signal-to-noise ratio, which may cause instability in gene
signatures. Utilizing other information may help to reduce the effect of randomly
generated differences in expression levels [38]. Without the incorporation of
genomic knowledge, remMap may select uninformative genes due to the random
noises in microarray data.
Apart from the limitations mentioned above, there are some drawbacks three
methods all have.
•

Different cancer types and subtypes are not considered. The inability of
taking cancer types and subtypes into consideration may lead to the failure
of identifying signature genes of certain type or subtype.

•

Different omics data have different noise level. For each data integration
method, its tolerance to noise in each type of omics dataset is unknown,
which may make the results questionable.
4.3

Conclusions

Research in data integration and in drug synergy analysis has mostly remained
isolated. Our study suggests that the application of data integration approach may
improve our understanding of targeted drug synergies. The emergence of data
integration methods will facilitate the process of variable selection for models to
predict drug synergies. Although the need for a systematic integrative analysis
method has not been fully addressed yet, there are various approaches that can be
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implemented in future studies. The major challenge of incorporating data
integration analysis into drug synergies study is to combine different types of omics
datasets and drug information. As more data are generated across multiple data
types, novel integration methodologies of future will further our understanding of
important biological processes of gene-gene and drug-gene interactions.
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